11. DOP08 Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBD. (21st January 2022) Authors: Sudhakar, P; Verstockt, B; Cremer, J; Verstockt, S; Sabino, J; Ferrante, M; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i058 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. DOP17 Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study. (21st January 2022) Authors: Lenfant, M; Verstockt, B; Sabino, J; Vermeire, S; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. DOP22 Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohn's Disease. (27th May 2021) Authors: Sudhakar, P; Andrighetti, T; Verstockt, S; Caenepeel, C; Ferrante, M; Sabino, J; Verstockt, B; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients. (25th January 2019) Authors: Creyns, B; Verstockt, B; Cremer, J; Ballet, V; Ferrante, M; Vermeire, S; Ceuppens, J; Van Assche, G; Breynaert, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S040 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. DOP29 Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy. (25th January 2019) Authors: Moens, A; van der Woude, C; Julsgaard, M; Sebastian, S; Arebi, N; Alzinaty, M; Humblet, E; Kok, K B; Sheridan, J; Gilletta De Saint-Joseph, C; Nancey, S; Rahier, J-F; Bossuyt, P; Cremer, A; Dewit, S; Eriksson, C; Hoentjen, F; Krause, T; Louis, E; Macken, E Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S041 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches. (15th January 2020) Authors: Verstockt, S; Verplaetse, N; Raimondi, D; Verstockt, B; Glorieus, E; De Decker, M; Hannes, L; Ballet, V; Vandeput, E; Moreau, Y; Ferrante, M; Laukens, D; Mana, F; De Vos, M; Vermeire, S; Cleynen, I Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S070 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. DOP34 Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn's Disease for modified Rutgeerts' score i2a and i2b categories: Individual patient data meta-analysis. (21st January 2022) Authors: Riviere, P; Pekow, J; Hammoudi, N; Wils, P; De Cruz, P; Wang, C; Mañosa, M; Ollech, J; Allez, M; Nachury, M; Kamm, M; Maya, A; Ferrante, M; Buisson, A; Singh, S; Laharie, D; Momar, D; Fumery, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience. (25th January 2019) Authors: Verstockt, B; Mertens, E; Outtier, A; Van Assche, G; Vermeire, S; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. (25th January 2019) Authors: Sandborn, W J; Ferrante, M; Bhandari, B R; Berliba, E; Hibi, T; D'Haens, G Geert R; Tuttle, J; Krueger, K; Friedrich, S; Durante, M; Arora, V; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis. (25th January 2019) Authors: Sandborn, W J; Sands, B; Kobayashi, T; Tuttle, J; Schmitz, J; Durante, M; Higgs, R; Canavan, J B; Siegel, R; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S059 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗